Translational Development Acquisition (TDAC) Total Liabilities (2023 - 2026)

Translational Development Acquisition's Total Liabilities history runs 4 years deep, the most recent figure standing at $6.9 million for Q1 2026.

• Quarterly Total Liabilities rose 8.46% year-over-year to $6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.9 million (up 8.46% YoY) and the FY2025 annual result came in at $6.6 million, up 5.34% from the prior year.
• Total Liabilities was $6.9 million for Q1 2026 at Translational Development Acquisition, up from $6.6 million in the prior quarter.
• Across five years, Total Liabilities topped out at $6.9 million in Q1 2026 and bottomed at $509679.0 in Q4 2023.
• A 4-year average of $5.6 million and a median of $6.4 million in 2025 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2024 — Total Liabilities jumped 1125.83% — and 2025, when it advanced 5.34%.
• Translational Development Acquisition's Total Liabilities stood at $509679.0 in 2023, then soared by 1125.83% to $6.2 million in 2024, then advanced by 5.34% to $6.6 million in 2025, then advanced by 4.82% to $6.9 million in 2026.
• Business Quant data shows TDAC's Total Liabilities at $6.9 million in Q1 2026, $6.6 million in Q4 2025, and $6.5 million in Q3 2025.